<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14</volume><submitter>Skalniak A</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>The standard care of schizophrenia patients is based on the assessment of their psychotic behavior, using interview-based, subjective scales that measure symptoms severity. We aimed at defining easily accessible and inexpensive blood-derived clinical diagnostic parameters that might serve as objective markers in the prediction of the effects of pharmacological treatment of schizophrenia patients.&lt;h4>Methods&lt;/h4>A total of 40 patients with schizophrenia diagnosis according to ICD 10 during psychotic decompensation were included in the study. Blood-based biochemical parameters, BMI and interview-based medical scales of symptom severity were determined - all at admission and after 12 weeks of standard pharmacological treatment.&lt;h4>Results&lt;/h4>The drops in scale values wer</pubmed_abstract><journal>Frontiers in psychiatry</journal><pagination>1082135</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10073498</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment.</pubmed_title><pmcid>PMC10073498</pmcid><pubmed_authors>Pilecki M</pubmed_authors><pubmed_authors>Donicz P</pubmed_authors><pubmed_authors>Smierciak N</pubmed_authors><pubmed_authors>Krzysciak W</pubmed_authors><pubmed_authors>Szwajca M</pubmed_authors><pubmed_authors>Skalniak A</pubmed_authors><pubmed_authors>Kozicz T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Immunological routine laboratory parameters at admission influence the improvement of positive symptoms in schizophrenia patients after pharmacological treatment.</name><description>&lt;h4>Introduction&lt;/h4>The standard care of schizophrenia patients is based on the assessment of their psychotic behavior, using interview-based, subjective scales that measure symptoms severity. We aimed at defining easily accessible and inexpensive blood-derived clinical diagnostic parameters that might serve as objective markers in the prediction of the effects of pharmacological treatment of schizophrenia patients.&lt;h4>Methods&lt;/h4>A total of 40 patients with schizophrenia diagnosis according to ICD 10 during psychotic decompensation were included in the study. Blood-based biochemical parameters, BMI and interview-based medical scales of symptom severity were determined - all at admission and after 12 weeks of standard pharmacological treatment.&lt;h4>Results&lt;/h4>The drops in scale values wer</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-05T12:18:30.249Z</modification><creation>2025-04-05T12:18:30.249Z</creation></dates><accession>S-EPMC10073498</accession><cross_references><pubmed>37032951</pubmed><doi>10.3389/fpsyt.2023.1082135</doi></cross_references></HashMap>